Au W Y, Kumana C R, Lee H K K, et al. Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. Blood, 2011, 118: 6535-6543
[2]
Bernard J, Weil M, Boiron M, et al. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood, 1973, 41: 489-496
[3]
Bernard J, Weil M, Jacquillat C I. Treatment of acute granulocytic leukemias. Ann Rev Med, 1974, 25: 39-50
[4]
Boiron M, Weil M, Jacquillat C, et al. (1969). Daunorubicin in the treatment of acute myelocytic leukaemia. Lancet, 1969, 293: 330-333
[5]
Breitman T R, Selonick S E, Collins S J. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA, 1980, 70: 2936-2940
[6]
Breitman T R, Collins S J, Keene B R. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood, 1981, 57: 1000-1004
[7]
Castaigne S, Chomienne C, Daniel M T, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood, 1990, 76: 1704-1709
Chen G Q, Zhu J, Shi X G, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia. As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR α/PML proteins. Blood, 1996, 88: 1052-1061
[10]
Chen G Q, Shi X G, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), I: As2O3 exerts dose-dependent dual effects on APL cells. Blood, 1997, 89: 3345-3353
Chen S J, Zhou G B, Zhang X W, et al. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood, 2011, 117: 6425-6437
[13]
Chen Z X, Xue Y Q, Zhang R, et al. A clinical and experimental study on all-trans retinoic acid treated acute promyelocytic leukemia patients. Blood, 1991, 78: 1413-1419
[14]
Chomienne C, Ballerini P, Balitrand N, et al. Retinoic acid therapy for promyelocytic leukemia. Lancet, 1989, 334: 746-747
[15]
Collins S J, Gallo R C, Gallagher R E. Continuous growth and differentiation of human myeloid leukemic cells in suspension culture. Nature, 1977, 270: 347-349
[16]
Daenen S, Vellenga E, van Dobbenbugh O A, et al. Retinoic acid as antileukemic therapy in a patient with acute promyelocytic leukemia and Aspergillus pneumonia. Blood, 1986, 67: 559-561
Ellison R R, Holland J F, Weil M, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood, 1968, 32: 507-523
[21]
Estey E H. Newly diagnosed acute promyelocytic leukemia: arsenic moves front and center. J Clin Oncol, 2011, 29: 2743-2746
[22]
Flynn P, Miller W, Weisdorf D, et al. Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observations. Blood, 1983, 62: 1211-1217
[23]
Fontana J A, Roger I S, Durham J P. The role of 13-cis retinoic acid in the remission induction of a patient with acute promyelocytic leukemia. Cancer, 1986, 57: 209-217
[24]
顾德謦. 中药“55”治疗白血病疗效的初步观察. 哈尔滨中医, 1964, 15: 24
[25]
关继仁. 白血病(49例临床分析). 黑龙江医学, 1958, 2: 22-34
[26]
Guo H X, Chen W, Liu L X, et al. Recent status of the effect of arsenic trioxide on colon cancer. Chin J Integr Trad West Med Dig, 2006, 14: 207-209
[27]
中医研究院西苑医院内科血液组. 白血病的中医治疗. 广东医学, 1974, 5: 31-37
[28]
Honma Y, Fujita Y, Kasukabe T, et al. Induction of differentiation of human acute non-lymphocytic leukemia cells in primary culture by inducers of differentiation of human myeloid leukemia cell line HL-60. Eur J Cancer Clin Oncol, 1983, 19: 251-261
Huang M E, Ye Y C, Chen S R, et al. All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia: report of 6 cases. Chin Med J, 1987, 100: 949-953
[31]
Huang M E, Ye Y C, Chen S R, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 1988, 72: 567-572
Liu L X, Zhu A L, Chen W, et al. Effect of arsenic trioxide on hepatocellular carcinoma and its mechanistic studies. Chin J Surg, 2005, 43: 33-36
[37]
Mervis J. Cancer research: ancient remedy performs new tricks. Science, 1996, 273: 578
[38]
Nilsson B. Probable in vivo induction of differentiation by retinoic acid acid of promyelocytes in acute promyelocytic leukemia. British J Haematol, 1984, 57: 365-371
[39]
Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood, 1999, 94: 3315-3324
[40]
Olsson I L, Breitman T R. Induction of differentiation of the human histiocytic lymphoma cell line U-937 by retinoic acid and cyclic adenosine 3'': 5''-monophosphate-inducing agents. Cancer Res, 1982, 42: 3924-3927
[41]
Breitman T R. Induction of terminal differentiation of l-IL-60 and fresh leukemic cells by retinoic acid, p.257. In: Revoltella R F, ed. Expression of Differentiated Functions in Cancer Cells. New York: Raven, 1982
[42]
Powell B L, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood, 2010, 116: 3751-3757
Rosenthal E. Chairman Mao''s cure for cancer. New York Times, May 6th, 2001
[45]
Sanz M A, Grimwade D, Tallman M S, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 2009, 113: 1875-1891
[46]
Sanz M A, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol, 2011, 29: 495-503
[47]
Sears D A. History of the treatment of chronic myelocytic leukemia. Am J Med Sci, 1988, 296: 85-86
[48]
Shen Z X, Chen G Q, Ni J H, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), II: clinical efficacy and pharmacokinetics in relapsed patients. Blood, 1997, 89: 3354-3360
[49]
Soignet S L, Maslak P, Wang Z G, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med, 1998, 339: 1341-1348
Tallman M S, Andersen J W, Schiffer C A, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med, 1997, 337: 1021-1028
[53]
Tallman M S, Altman J K. How I treat acute promyelocytic leukemia. Blood, 2009, 114: 51260-51235
[54]
Warrell Jr R P, Frankel S T, Miller Jr W H, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med, 1991, 324: 1385-1393
